Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
May 26, 2016
SEATTLE, May 26, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Cigna has issued a positive Medical Coverage Policy decision for the Prosigna® Breast Cancer Gene Signature Assay.  Cigna and its ro...
May 24, 2016
SEATTLE, May 24, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Jefferies 2016 Healthcare Conference in New York, NY. Brad Gray, President and Chief...
May 9, 2016
SEATTLE, May 09, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of molecular diagnostic testing products and life science tools for translational research, today announced that Aetna has added the Prosigna® Breast Cancer Gene Signature Assay to its Tumor Markers Clinical Policy Bulletin.  Aetna and its more ...
May 5, 2016
SEATTLE, May 05, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the first quarter ended March 31, 2016. First Quarter Financial Highlights Total revenue of $14.7 million, 27% year-over-y...
Apr 27, 2016
SEATTLE, April 27, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV. Brad G...
Apr 18, 2016
NEW ORLEANS, April 18, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today presented the first proof-of-concept data from its novel multiplexed digital immunohistochemistry (IHC) technology at the American Association for Cancer ...
Apr 14, 2016
nCounter Vantage Products Enable Simultaneous Analysis of DNA, RNA, and Protein to Expand Capabilities In Cancer Research, Including Immuno-Oncology Multiple New Products to be Featured at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans SEATTLE, April 14, 2016 (GLOBE NEWSWIRE) -- NanoString Technologi...
Apr 13, 2016
SEATTLE, April 13, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release first quarter 2016 financial results after the close of trading on Thursday, May 5, 2016. Company management will host...
Apr 11, 2016
SEATTLE and MARSEILLE, France, April 11, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and HalioDx SAS, a diagnostic company in immuno-oncology, today announced they have entered into an agreement to jointly develop and commercia...
Mar 21, 2016
SEATTLE, March 21, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Noridian Healthcare Solutions, LLC, a Medicare Administrative Contractor (MAC) for two Medicare jurisdictions covering 13 states, has issued fa...
Mar 10, 2016
SEATTLE and DANVERS, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, and Cell Signaling Technology (CST), a worldwide provider of antibodies, have reached an agreement to use highly validated antibodies from CST in...
Feb 29, 2016
SEATTLE, Feb. 29, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the fourth quarter and year ended December 31, 2015. Fourth Quarter Financial HighlightsTotal revenue of $22.3 million, 43% y...
Feb 29, 2016
SEATTLE, Feb. 29, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the US and Canada, through a subsidiary, to develop and commercia...
Feb 22, 2016
SEATTLE, Feb. 22, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company's management is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston. Brad Gray, Presiden...
Feb 12, 2016
SEATTLE, Feb. 12, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company will release fourth quarter 2015 financial results after the close of trading on Monday, February 29, 2016. Company management will ...
= add release to Briefcase